SynthesisDeutsches Arzteblatt international2021
Imaging of Prostate Cancer.
Synthesis in Deutsches Arzteblatt international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Prognostic value of baseline circulating tumor DNA levels in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Preclinical and First-In-Human Evaluation ofACS omega · 2026Article
- Clinical Impact of PSMA PET Fusion-Based RT Planning on Dosimetry and PSA Response in Prostate Cancer.Journal of clinical medicine · 2026Article
- Context-level machine learning to improve the identification of lymph node and bone metastases in prostate cancer patients using [EJNMMI physics · 2025Article
- Reduction of Negative Charge in Mercaptoacetyl-Based Chelators Influences the Biodistribution of Prostate-Specific Membrane Antigen-Targeting Pseudopeptides Labeled with Technetium-99m.ACS pharmacology & translational science · 2025Article
- Article
- Review
- Article
- Prostate biopsy in patients without rectal access: a systematic review and proportional meta-analysis.Central European journal of urology · 2025Review
- Advances in imaging and artificial intelligence for precision diagnosis and biopsy guidance in prostate cancer.Frontiers in oncology · 2025Review
- Imaging of prostate micro-architecture using three-dimensional wide-field optical coherence tomography.Biomedical optics express · 2024Article
- Comparing the diagnostic value ofTranslational andrology and urology · 2024Article
- Radiology of fibrosis part III: genitourinary system.Journal of translational medicine · 2024Review
- Review
- Value of machine learning-based transrectal multimodal ultrasound combined with PSA-related indicators in the diagnosis of clinically significant prostate cancer.Frontiers in endocrinology · 2023Article
- The Treatment of Metastatic, Hormone-Sensitive Prostatic Carcinoma.Deutsches Arzteblatt international · 2022Article
- Qualitative Data Are Lacking.Deutsches Arzteblatt international · 2022Article
- In Reply.Deutsches Arzteblatt international · 2022Article
- [Artificial intelligence (AI) in radiology? : Do we need as many radiologists in the future?]Der Urologe. Ausg. A · 2022Review
- Contrast-Enhanced Ultrasound-Magnetic Resonance Imaging Radiomics Based Model for Predicting the Biochemical Recurrence of Prostate Cancer: A Feasibility Study.Computational and mathematical methods in medicine · 2022Article
Corrections and comments
- Commented on by
- Commented on byIn Reply.2022
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer is the most common type of solid tumor in men and the second most common cause of cancer-related death in males in Germany. The conventional strategy for its primary detection, i.e., systematic ultrasound-guided prostate biopsy in men who have elevated PSA levels and/or positive findings on digital rectal examination, fails to reveal all cases. The same is true of the use of conventional computed tomography (CT), magnetic resonance imaging (MRI), and skeletal scintigraphy for the early detection of recurrences and distant metastases.
methodsThis review is based on pertinent publications retrieved by a selective search, including the German clinical practice guideline on prostate cancer and systematic review articles.
resultsProspective multicenter trials have shown that the detection of clinically significant prostate cancer is markedly improved with multiparametric MRI (mpMRI) and MR/TRUS fusion biopsy (TRUS = transrectal ultrasonography), compared to conventional systematic biopsy. A recent Cochrane review showed that the rate of overdiagnosis of low-risk prostate cancer was reduced with mpMRI and MR/TRUS fusion biopsy compared with conventional systematic biopsy (95/1000 vs. 139/1000), and that clinically significant prostate cancer was more reliably detected (sensitivity 72% vs. 63%), albeit with slightly lower specificity (96% vs. 100%). Prostate- specific membrane antigen (PSMA) hybrid imaging improves the detection of lymphogenic and bony metastases in patients with high-risk prostate cancer. PSMA hybrid imaging is most commonly used to detect biochemical recurrences. A metaanalysis showed that the detection rate depends on the PSA concentration: 74.1% overall, 33.7% with PSA <0.2 ng/mL, and 91.7% with PSA ≥= 2.0 ng/mL.
conclusionThe appropriate use of mpMRI and MR/TRUS fusion biopsy improves the initial detection of prostate cancer as well as the assessment of the prognosis. PSMA hybrid imaging is useful for the staging of high-risk patients and for the detection of recurrences. These methods are now recommended in the German clinical practice guideline on prostate cancer as well as in guidelines from other countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.